Pfizer Expected to Post Q1 2018 Earnings of $0.73 Per Share (PFE)
Pfizer (NYSE:PFE) – Equities researchers at Jefferies Group issued their Q1 2018 EPS estimates for Pfizer in a research note issued to investors on Friday, April 13th. Jefferies Group analyst I. Hilliker anticipates that the biopharmaceutical company will post earnings of $0.73 per share for the quarter. Jefferies Group has a “Hold” rating and a $38.00 price objective on the stock. Jefferies Group also issued estimates for Pfizer’s FY2020 earnings at $3.18 EPS, FY2021 earnings at $3.49 EPS and FY2022 earnings at $3.89 EPS.
PFE has been the subject of a number of other reports. SunTrust Banks reiterated a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morningstar set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. BMO Capital Markets set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, March 6th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a report on Monday, January 15th. Finally, Bank of America set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $39.20.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.47 earnings per share.
Several large investors have recently made changes to their positions in PFE. ADAMCAPITAL Gestao de Recursos Ltda. purchased a new position in Pfizer in the fourth quarter worth $59,318,000. Cambridge Investment Research Advisors Inc. boosted its position in Pfizer by 1.3% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 826,803 shares of the biopharmaceutical company’s stock worth $29,947,000 after purchasing an additional 10,868 shares during the last quarter. Certified Advisory Corp purchased a new position in Pfizer in the fourth quarter worth $235,000. Fairfield Bush & CO. boosted its position in Pfizer by 14.4% in the fourth quarter. Fairfield Bush & CO. now owns 46,194 shares of the biopharmaceutical company’s stock worth $1,672,000 after purchasing an additional 5,800 shares during the last quarter. Finally, Wagner Wealth Management LLC purchased a new position in Pfizer in the fourth quarter worth $197,000. 71.19% of the stock is currently owned by institutional investors.
In related news, insider Charles H. Hill sold 42,393 shares of Pfizer stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Douglas M. Lankler sold 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total value of $1,844,500.00. Following the transaction, the insider now directly owns 133,057 shares in the company, valued at approximately $4,908,472.73. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is owned by insiders.
Pfizer declared that its board has authorized a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.